日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

MEK 抑制剂曲美替尼对患者来源的胰腺癌异种移植瘤生长的抑制作用,可通过与表皮生长因子受体/HER2 抑制剂拉帕替尼联合治疗得到增强

Walters Dustin M, Lindberg James M, Adair Sara J, Newhook Timothy E, Cowan Catharine R, Stokes Jayme B, Borgman Cheryl A, Stelow Edward B, Lowrey Bryce T, Chopivsky Maria E, Gilmer Tona M, Parsons John T, Bauer Todd W

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

黑色素瘤中MEK2突变和BRAF扩增同时发生会导致对BRAF和MEK抑制剂产生耐药性。

Villanueva, Jessie; Infante, Jeffrey R; Krepler, Clemens; Reyes-Uribe, Patricia; Samanta, Minu; Chen, Hsin-Yi; Li, Bin; Swoboda, Rolf K; Wilson, Melissa; Vultur, Adina; Fukunaba-Kalabis, Mizuho; Wubbenhorst, Bradley; Chen, Thomas Y; Liu, Qin; Sproesser, Katrin; DeMarini, Douglas J; Gilmer, Tona M; Martin, Anne-Marie; Marmorstein, Ronen; Schultz, David C; Speicher, David W; Karakousis, Giorgos C; Xu, Wei; Amaravadi, Ravi K; Xu, Xiaowei; Schuchter, Lynn M; Herlyn, Meenhard; Nathanson, Katherine L

Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.

拉帕替尼对小鼠雌激素受体阴性乳腺肿瘤发展的影响

Strecker Tracy E, Shen Qiang, Zhang Yun, Hill Jamal L, Li Yuxin, Wang Chunyu, Kim Hee-Tae, Gilmer Tona M, Sexton Krystal R, Hilsenbeck Susan G, Osborne C Kent, Brown Powel H

The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics)

抗癌药物(药物或生物制剂)转化研究工作组的研发路径

Schilsky, Richard L; Gordon, Gary; Gilmer, Tona M; Courtneidge, Sara A; Matrisian, Lynn M; Grad, Oren; Nelson, William G